Andere talen Ascendis Pharma A/S

Aandelen

ASND

US04351P1012

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 20-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
176,90 ^USD	+3,63%		+3,57%	+28,50%

13/06	ASCENDIS PHARMA A/S : Oppenheimer handhaaft koopadvies	ZM
11/06	Allarity Therapeutics, Inc kondigt wijzigingen aan in de raad van bestuur	CI

Andere talen

Allarity Therapeutics, Inc Announces Changes to Board of Directors	11/06
Ascendis Pharma Set to Exceed Q2 Expectations, RBC Says	10/06
Ascendis Pharma A/S : COACH Trial Interim Topline Week 26 Data	09/06
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial	09/06
Ascendis Pharma A/S Announces Week 26 Interim Analysis Results from Its Ongoing Coach Trial	09/06
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	02/06
Ascendis' New Drug Application for Investigational Drug to Treat Genetic Disorder Accepted by FDA for Priority Review	02/06
Ascendis Pharma A/S Announces Fda Acceptance of Transcon®? Cnp Nda for Priority Review	02/06
FDA Accepts TransCon® CNP NDA for Priority Review	02/06
European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading	29/05
ESPE & ESE 2025: PaTH Forward 4-Year Data	16/05
ESPE & ESE 2025: ApproaCH 52-Week Bone Morphometry	16/05
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading	14/05
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)	13/05
Ascendis Pharma A/S Announces New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon CNP (navepegritide)	13/05
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	13/05
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism	12/05
Ascendis Pharma A/S Announces New 4-Year Data Shows Sustained Response to TransCon PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism	12/05
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Down 1% for Week	09/05
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	08/05
Ascendis Likely to Benefit From Promising Yorvipath Launch, Morgan Stanley Says	05/05
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025	05/05
Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025	05/05
Ascendis Pharma Q1 Loss Narrows, Revenue Rises	01/05
Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2025	01/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ascendis Pharma A/S

Aandelen

ASND

US04351P1012

Biotechnologie & Medisch Onderzoek

Andere talen

Filters